Public-registry site landscape for NCT07733349, a Parkinson's Disease study sponsored by Shanghai UniXell Biotechnology Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07733349 (registry record) |
| Sponsor | Shanghai UniXell Biotechnology Co., Ltd |
| Condition(s) | Parkinson's Disease |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of the facilities listed on this trial — 3 other studies are actively recruiting Parkinson's Disease patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07733349 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →